The first cut-free endoscopic treatment for diabesity, ForePass R is able to replicate the most common types of metabolic surgery (Roux-en-Y Gastric Bypass, RYGB, BilioPancreatic Diversion, and Sleeve Gastrectomy). The first version of our product is aimed at RYGB.
ForePass R replicates the three most common metabolic surgeries without making a single cut
Conclusion: ForePass R reduces body weight, glycemia and insulin resistance, and liver fat deposition to the same level of gastric bypass surgery
We demonstrated a full reversal of diabetes and NASH, and weight loss, to levels not statistically different from gastric bypass surgery
Pre-clinical studies in the USA and Italy have shown that the efficacy of ForePass R may be unprecedented, and even better than RYGB. Data from our one-month study includes:
This represents a widely underserved patient population of at least 22 million people just in the USA and EU
Widely considered safe, but ineffective on diabetes.
The fact that balloons move throughout the stomach fails to maximize weight loss
Current drugs are not very helpful for weight loss when it comes to people with BMIs over 38
ForePass R is an extremely promising technology which may allow us to deliver the same benefits of metabolic surgery but without the complications from a surgical procedure
The rodent data obtained with ForePass shows that the device is expected to reach the same unmatched efficacy of metabolic surgery, primarily a remission of insulin resistance and substantial weight loss.
ForePass could allow many more people to access the efficacy that metabolic surgery is known for. Its elegant anchoring system could ensure the required safety that so many other devices in the space have not been able to achieve